🇦🇺Australia
TGA Non-Compliance Fines
1 verified sources
Definition
Annual product reviews identify trends in quality data; failure risks TGA enforcement including fines for GMP breaches.
Key Findings
- Financial Impact: AUD 20,000 - 500,000 per violation; 2-5% production downtime costs
- Frequency: Annual audits; ongoing trending required
- Root Cause: Manual data analysis delays and errors in trending
Why This Matters
This pain point represents a significant opportunity for B2B solutions targeting Pharmaceutical Manufacturing.
Affected Stakeholders
Quality Manager, Regulatory Affairs, Manufacturing Director
Action Plan
Run AI-powered research on this problem. Each action generates a detailed report with sources.
Methodology & Sources
Data collected via OSINT from regulatory filings, industry audits, and verified case studies.
Evidence Sources:
Related Business Risks
Cost of Poor Quality from Trending Failures
AUD 100,000+ per failed batch; 1-3% of production costs
Idle Capacity from Review Delays
AUD 5,000-10,000/day idle bioreactor; 5-10% capacity loss
Kosten durch TGA-GMP-Abweichungen bei Änderungsdokumentation
Estimated: AUD 70,000–250,000 per major GMP inspection cycle in extra remediation labour, consulting and TGA‑driven compliance costs due to deficient change control documentation.
Produktivitätsverlust durch manuelle Änderungsdokumentation
Estimated: 400–1,200 hours/year of QA and production time, equivalent to approximately AUD 32,000–144,000 per year in lost productive capacity due to manual change control documentation.
Verzögerter Marktzugang durch langsame Änderungsfreigaben
Estimated: AUD 100,000–500,000 per year in cost‑of‑capital and opportunity cost from 1–5 day delays to batch release or implementation of revenue‑relevant changes caused by slow change control documentation and approval.
GMP CAPA Non-Compliance Fines
AUD 20,000-100,000 per GMP violation (batch rejection + rework costs); typical 2-5% production loss from deviations[3][6]